

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Micro-X Ltd
ABN	21 153 273 735

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Hannebery
Date of last notice	3 October 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Domain Capital Biotech Investments Pty Limited (Mr Hannebery is a director of this entity and is a beneficiary) Mrs Robyn Gould (spouse of Mr Hannebery) Silica Investments Pty Limited (Mr Hannebery is a beneficiary of this entity)
Date of change	18 January 2018
No. of securities held prior to change	<u>Direct</u> 696,556 Unlisted Options exercisable at \$0.575 (57.5 cents) on or before 31/12/19 1,393,114 Unlisted Options exercisable at \$0.625 (62.5 cents) on or before 31/12/19 262,500 Ordinary Fully Paid Shares <u>Indirect</u> 3,093,450 Ordinary Fully Paid Shares

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	Fully Paid Ordinary Shares
Number acquired	
Number disposed	349,600
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – Distribution from Trust
No. of securities held after change	<p><u>Direct</u></p> <p>696,556 Unlisted Options exercisable at \$0.575 (57.5 cents) on or before 31/12/19</p> <p>1,393,114 Unlisted Options exercisable at \$0.625 (62.5 cents) on or before 31/12/19</p> <p>262,500 Ordinary Fully Paid Shares</p> <p><u>Indirect</u></p> <p>2,743,850 Ordinary Fully Paid Shares</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off market transfer - Distribution of Ordinary Shares from Domain Capital Biotech Investments held on Trust

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	Indirect
Name of registered holder (if issued securities)	Domain Capital Biotech Investments Pty Limited
Date of change	18 January 2018
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	349,600
Interest acquired	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	349,600
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Nil – Distribution from Trust
Interest after change	349,600

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only